Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR

NCT ID: NCT04723953

Last Updated: 2022-10-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 89 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-26
• Study Completion Date: 2022-09-30

Brief Summary

Myocardial infarction is the most common cause of high mortality in the modern world. The short-term survival rate of ST-elevated myocardial infarction (STEMI) has been dramatically increased in the past decades thanks to primary coronary intervention and standardization of treatment. However, the long-term prognosis of patients with acute myocardial infarction (AMI) is still poor, especially in the aging population, due to heart failure related to inappropriate myocardial fibrosis and subsequent left ventricular (LV) remodeling. Despite the amelioration of STEMI management, LV remodeling still occurs in approximately 1/3 of all STEMI patients. Therefore, early identification of such patients may help the optimization of therapy and eventually the outcomes.

One characteristic of activated cardiac fibroblasts is the expression of FAP (fibroblast activation protein). A tracer (FAP inhibitor) for positron emission tomography that targets FAP has been used to measure relative FAP density indicative of activated fibroblasts in different cancer entities. However, whether it can reliably assess myocardial fibrosis and predict the poor prognosis caused by LV remodeling is not yet known. Therefore, We aim to observe active myocardial fibrosis process in patients with AMI, and analyze its relationship with the patients'prognosis in a longitudinal study through 68Ga-FAPI PET/MRI.

Conditions

Myocardial Remodeling After AMI

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Acute myocardial infarction patient group

Group Type: EXPERIMENTAL

68Ga-FAPI PET/MRI

Intervention Type: DIAGNOSTIC_TEST

PET and MRI in patients with acute myocardiac infarction are simultaneously analyzed using hybrid PET/MRI device for monitoring myocardial fibrosis and function.

Interventions

68Ga-FAPI PET/MRI

PET and MRI in patients with acute myocardiac infarction are simultaneously analyzed using hybrid PET/MRI device for monitoring myocardial fibrosis and function.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• between 18-75 years old
• diagnosed with coronary angiography
• performed percutaneous coronary intervention，with successful myocardial reperfusion

Exclusion Criteria

• unstable hemodynamics
• MR contraindications (such as pacemaker or nerve stimulator or metal foreign body, high fever, severe renal failure, etc.)
• Claustrophobia

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shanghai Ruijin Hospital

Shanghai, , China

Countries

China

References

Qiao X, Wang H, Meng H, Xi Y, Feng DD, Li B, Yan X, Zhang M, Huang Q. Multi-modality deep learning-based [68Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction. Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):3944-3959. doi: 10.1007/s00259-024-06850-3. Epub 2024 Jul 26.

Reference Type: DERIVED

PMID: 39060373 (View on PubMed)

Other Identifiers

(2020)CER(152)

Identifier Type: -

Identifier Source: org_study_id